NCT06629909View on ClinicalTrials.gov

Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Liver Cirrhosis
Interventions
DRUG

Secretome

3 ml Injection of secretome for 8 times two weeks apart

Trial Locations (1)

10150

Liver Clinic Prof Ali Sulaiman, Jakarta

Sponsors

Lead Sponsor

Baermed
All Listed Sponsors
collaborator

Tarumanagara University

OTHER

collaborator

Liver Clinic Prof Ali Sulaiman

UNKNOWN

collaborator

Pelni Hospital

UNKNOWN

lead

Baermed

OTHER

NCT06629909 - Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial | Biotech Hunter | Biotech Hunter